ValiRx PLC (LSE:VAL) - Share price - Overview

Stock Report

ValiRx PLC VAL

Last Price
GBX2.40

Day Change
-0.02|-1.03%

As of 26/05/2017
16:12:46 BST | GBX
Minimum 15 Minutes Delay.

Last Close2.43p
Day Range2.30 - 2.48
Mkt Cap3.20Mil
52-Wk Range2.06 - 11.49
Yield %0.00
ISINGB00BWWYSP41
Volume1,237,487
P/E-0.28
P/SInfinity
P/CF-0.33

Share Price

Total Returns 26/05/2017

 Chg (%)  
More ...
ValiRx PLC-4.00 
FTSE 100 TR GBP4.15
 
Financials
201420152016
More ...
Income Statement
Turnover0.090.000.00
Operating Profit-3.14-2.70-4.51
Net Profit-3.24-1.85-5.13
Reported EPS-13.50-5.63-8.54
Balance Sheet
Current Assets1.242.432.13
Non Current Assets2.382.702.84
Total Assets3.625.124.96
Current Liabilities0.840.592.59
Total Liabilities0.840.592.59
Total Equity2.794.532.37
Cash Flow
Operating Cash Flow-3.32-2.98-4.23
Net Change in Cash-0.51-0.220.33
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
--------
--------

Regulatory News

Director Dealings
TradedActionNotifierPriceAmountValue
More ...
15/03/2017PurchaseMr. Gerry Desler2.50400,00010,000.00
15/03/2017PurchaseDr. Satu Vainikka2.50400,00010,000.00
15/03/2017PurchaseDr. George Morris2.50400,00010,000.00

Company Profile

ValiRx PLC is a biopharmaceutical company. The Company is engaged in developing technologies and products in oncology therapeutics and diagnostics focused on the treatment of cancer and associated Biomarkers, specializing in epigenomic & genetic analysis.

Sector

Biotechnology

Market Position

1709 of 1851 Companies

Index

FTSE AIM All Share

Outlook

(05/05/2017) "...Our clinical trials have performed well and in line with expectations and the company is very much looking forward to the next stage of its clinical trials"

Next Event 30/05/2017

Next AGM
Ratios
CompSecMkt
More ...
PER (E)0.0015.0716.87
Div Yld (E)0.003.604.05
PEG (E)0.000.420.72
ROCE-685.46187.8415.97
Op Mrgn0.00-6.501.61
EPS Grwth0.0056.9427.17
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanOliver de Giorgio-Miller
Chief Executive OfficerDr. Satu Vainikka
Finance DirectorMr. Gerry Desler
Company SecretaryMr. Kevin Alexander
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.